Clinical trial
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
NCT00542451
Study timeline
Study start (unknown)2007-10-01Date precision: month
Registry last updated2024-06-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Carcinoma of the Breastunresolved
Interventions
PaclitaxelDRUG · verified · RxNorm: paclitaxel
TrastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Brigham and Women's Hospitalcollaborator
Beth Israel Deaconess Medical Centercollaborator
Massachusetts General Hospitalcollaborator
Genentech, Inc.collaborator
Mapped research locations
BostonMassachusetts, United States4New YorkNew York, United States2BaltimoreMaryland, United States1St LouisMissouri, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1ClevelandOhio, United States1DurhamNorth Carolina, United States1IndianapolisIndiana, United States1Chapel HillNorth Carolina, United States1BurlingtonVermont, United States1MaywoodIllinois, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00542451 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.